INSM: BRINSUPRI's blockbuster launch and expanding pipeline set the stage for sustained high growth

BRINSUPRI's launch has exceeded expectations, with first-year revenue projected at $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into comorbid COPD and asthma populations, strong international prospects in Japan, and a robust pipeline—including TPIP and gene therapie…